For many companies building in New York, the challenge isn’t growth itself. It’s how quickly operational, governance, regulatory, and litigation issues start to matter once that growth accelerates.

The Game Developers Conference 2026 brought more than 20,000 developers, publishers, investors, and platform stakeholders to San Francisco this year.

Artificial intelligence remained the defining theme of 2025, shaping both the scale and direction of capital flows.

Among all funding stages, Series C emerged as the breakout performer of 2025.

After years of volatility, 2025 signaled a pivotal moment for the venture capital market.

Client trust goes hand in hand with a strong data privacy program.

Government shutdowns are becoming a more persistent threat; is your IPO ready?

As life sciences companies mature, intellectual property often becomes both their most valuable and most scrutinized asset.

As early-stage life sciences companies prepare for their next financing or partnership, intellectual property due diligence is often the first, and most consequential, checkpoint.

Why do some life sciences companies stall between Series B and IPO?

Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets.